Funxional Therapeutics Completes Phase I Trial Of Anti-Inflammatory Drug

Funxional Therapeutics has completed the first phase I study of FX125L, an orally available small molecule which belongs to Broad Spectrum Chemokine Inhibitors (BSCIs).

FX125L, an Anti-Inflammatory Drug, was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed, said the company. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

Konstantinos Efthymiopoulos, CEO of Funxional, said: We are extremely pleased with the outcome of this initial clinical study with FX125L. The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L.